‹ Back

Why MedTech Companies Are Rethinking How They Operate

Building outcome-oriented organizations for sustainable growth

By CAHIR Solutions  |  February  2026  |  MedTech Strategy

 

 

Revenue growth has been the primary driver of value in MedTech. According to Bain & Company, every 100 basis points of revenue growth adds roughly two turns of forward enterprise value. Revenue growth contributes to total shareholder returns seven to nine times more than all other levers combined.

But here is the shift: growth in MedTech is no longer driven by product innovation alone.

In an environment shaped by pricing pressure, regulatory complexity, supply chain disruption, and shifting care delivery models, the most successful companies are fundamentally reimagining their operating models to deliver outcomes, not just products.

 

The Industry at a Glance

$584B Global MedTech revenue in 2025

6–7% Projected annual growth rate

1 in 4 Companies growing profitably above industry average

 

The global medical device market is projected to grow from $719 billion in 2026 to roughly $1.2 trillion by 2035. Yet beneath these headline figures, a stark divergence is forming. Top-quartile MedTech companies are growing revenue at an 11% CAGR, while bottom-quartile companies are seeing margin erosion accelerate. Only 25% of companies are expected to improve both revenue growth and margins over the next two years.

 

Why Legacy Operating Models Are Breaking Down

Many MedTech companies built their operating models during decades of steady growth driven by product innovation and geographic expansion. These structures—organized around functional silos, regional matrices, and diffused decision-making—served well in a predictable, volume-driven market.

 

Today, they are actively constraining performance. Here is why:

 

• Cross-functional misalignment. Value levers are deeply interconnected across portfolio, commercial, R&D, and supply chain. Legacy silos can take months or years to align on a single meaningful change.
• Diffused accountability. Complex matrix structures make it difficult to execute transformation at speed. Business units manage portfolios, regions manage commercialization, and operations oversees manufacturing—all separately.
• Trapped efficiencies. Many cost transformation efforts have been limited to one-off actions. Comprehensive approaches can reduce total cost baselines by 7–12% and increase gross margins by up to 3 percentage points.
• External pressure is mounting. Hospital budget constraints, 950+ FDA-authorized AI/ML devices, tariff uncertainty, and CMS adding 500+ procedures to the ASC Covered Procedures List are all reshaping competitive dynamics.

 

Four Operating Models Gaining Traction

There is no single transformation playbook. The right model depends on your strategy, portfolio mix, and organizational maturity. But four archetypes are proving most effective across the industry today:

 

Integrated Business Units

Full P&L ownership within each business unit, with R&D, supply chain, and commercial reintegrated under a single leader. Best for multi-segment companies seeking clear accountability and faster decisions.

 

Therapy-Focused Structures

Organized around clinical areas (cardiovascular, orthopedics, neuroscience) rather than product categories. Aligns the entire organization around patient pathways and clinical outcomes. Best for companies concentrated in high-growth therapeutic areas.

 

Platform-Based Models

Shared digital, data, and operational platforms serving multiple business units. Devices become entry points into analytics, monitoring, and service ecosystems. Best for companies moving from hardware-first to ecosystem-first strategies.

 

Value-Driven Commercial Models

Blended field and remote sales, omnichannel engagement, and AI-driven customer segmentation. Best for companies optimizing commercial spend. Blended channels have been shown to grow at 3x the rate of field-only approaches.

 

What Leading Companies Are Doing Differently

Across the industry, a clear pattern is emerging among top performers:

 

• Simplifying operating models. Companies are moving back to divisional structures, giving business units greater autonomy and full P&L ownership, while centralizing shared services like IT, HR, and finance.

• Accelerating strategic carve-outs. Healthcare carve-out deals grew at a 17% CAGR from 2010 to 2024. Carve-outs have outperformed buyouts by nearly 20 percentage points in internal rate of return.

• Industrializing AI. Leading players are moving beyond pilot projects. Johnson & Johnson generated 900 generative AI use cases, then focused resources on the highest-value projects. AI centers of excellence are becoming permanent fixtures.
• Funding transformation through procurement. Companies starting cost programs with procurement are generating 7–12% reductions in total external spend, with up to 30% savings in high-priority categories—freeing capital for broader transformation.

 

It Is Not Just About the Org Chart

Structural design alone is not enough. Embedding an outcome mindset requires deliberate investment in four enablers:

 

 

Why This Matters Now

The next 12 to 24 months represent a critical window. The valuation gap between leaders and stragglers is widening. Care delivery is being reconfigured as procedures shift to ambulatory settings. AI capability compounds over time—companies without it may become acquisition targets rather than acquirers. And more than $1 trillion of annual U.S. healthcare spend is expected to shift toward digital-first, data-powered care.

 

The bottom line: MedTech companies that combine differentiated innovation with advanced operating models and AI-enabled capabilities will be best positioned to deliver long-term growth. Those who act now can create differentiated outcomes and free up capacity to reallocate toward higher top-line growth—performance that investors will reward.

 

At CAHIR Solutions, we partner with health systems, agencies, and MedTech organizations to scale technology-enabled care models that improve outcomes, patient experience, and operational performance. Whether you are navigating operating model transformation, building AI readiness, or strengthening governance, we can help you move from strategy to execution.

 

Ready to explore what this means for your organization?

Visit us at cahir.ai or reach out to start the conversation.

 

Sources:

• Bain & Company, "Four New Trends Reinforce Medtech's Core Playbook" (2025)

• EY, "Pulse of the MedTech Industry 2025"

• McKinsey & Company, "The Transformation Imperative" (2025)

• BCG, "Turning Cost Pressure into Performance in Medtech" (2025)

• Deloitte, "Three Key Trends Likely to Shape Medtech in 2026"

• PwC, "Next in Medtech 2025"

• Today's Medical Developments, "2026 Forecast"